Latigo Biotherapeutics filed for an IPO

Latigo Biotherapeutics, a Thousand Oaks, California-based developer of non-opioid pain medicines, filed for an IPO with the SEC on July 17, 2026. The clinical-stage biotechnology company plans to raise $100 million and list on the Nasdaq under the ticker symbol LTGO. 

The Blue Owl Capital Inc.-backed clinical-stage developer of non-opioid pain medicines has one drug candidate in late-stage trials that has shown a roughly 50% greater analgesic effect than Vicodin, a comparable opioid, according to its filing Friday with the US Securities and Exchange Commission.

Key IPO Details

Ticker Symbol: LTGO
Target Exchange: Nasdaq Global Select Market
Underwriters: Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities
Target Amount: Approximately $100 million
Pipeline Highlights: The company is advancing LTG-001 (for acute pain) and LTG-321 (for osteoarthritis). Their lead candidate has shown a roughly 50% greater analgesic effect compared to the opioid Vicodin in trials.